CEL-SCI Corp CVM:NYSE American

Last Price$3.13Cboe Real-Time Last Sale as of 3:53PM ET 5/20/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change0.00(0.00%)
Bid (Size)$3.12 (100)
Ask (Size)$3.14 (250)
Day Low / High$2.96 - 3.21
Volume689.2 K

Cel-Sci's Multikine Immunotherapy Yields 14.1% Five-Year Survival Benefit in Head, Neck Cancer

10:27AM ET 6/28/2021 MT Newswires
Cel-Sci (CVM) said Monday that its Multikine immunotherapy yielded significant overall survival benefit in patients with advanced and primary squamous cell carcinoma of the head and neck.

Data obtained from a phase 3 trial showed that patients had an overall survival benefit of 14.1% with overall survival of 62.7% at five years for those receiving the Multikine treatment regimen followed by surgery and radiotherapy therapy, but not chemotherapy, as part of their standard of care. No safety issues were observed for Multikine in the treated population, according to the company.

CEL-SCI said it plans to seek US Food and Drug Administration approval for Multikine based on the immunotherapy's demonstrated significant overall survival benefit and favorable safety profile.

Price: 18.00, Change: -7.08, Percent Change: -28.23